Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
20 DE OUT DE 2026Por Administrador FynarkFonte: CNBC
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
Fonte original: https://www.cnbc.com/2026/10/20/novo-cagrisema-women-weight-loss-analysis.html
Notícias relacionadas
Global · 20 DE OUT DE 2026
Anthropic in talks with neocloud Nscale over second multibillion-dollar deal, source tells CNBC
Global · 20 DE OUT DE 2026
Turkey submits Saudi-Pakistan defence pact to parliament for ratification, sources say - Reuters
Global · 20 DE OUT DE 2026
Apple shares aren't cheap. Here's how to get long for less
Global · 20 DE OUT DE 2026